[SCHEDULE 13G/A] Ascendis Pharma A/S American SEC Filing
Janus Henderson Group plc reported a significant minority holding in Ascendis Pharma A/S American Depositary Shares. The filing shows an aggregate holding of 4,427,792 ADSs, representing 8.0% of the class, with shared voting and shared dispositive power over those shares. The filer is organized in Jersey and lists a UK principal office; the issuer is headquartered in Hellerup, Denmark.
One Janus Henderson subsidiary, JHIUS, may be deemed the beneficial owner of 4,328,772 ADSs (7.8%) with corresponding shared voting and dispositive power. The filing includes a certification that the securities were acquired in the ordinary course of business and not to change or influence control, and attaches a power of attorney authorizing named officers to file required reports.
Janus Henderson Group plc ha segnalato una partecipazione minoritaria significativa nelle American Depositary Shares di Ascendis Pharma A/S. La comunicazione indica un detenuto complessivo di 4,427,792 ADS, pari all'8.0% della classe, con poteri di voto e di disposizione condivisi su tali azioni. Il dichiarante 猫 costituito a Jersey e dichiara un ufficio principale nel Regno Unito; l'emittente ha sede centrale a Hellerup, in Danimarca.
Una controllata di Janus Henderson, JHIUS, potrebbe essere considerata il beneficiario effettivo di 4,328,772 ADS (7.8%) con i corrispondenti poteri di voto e di disposizione condivisi. La comunicazione include una certificazione che i titoli sono stati acquisiti nell'ordinaria attivit脿 commerciale e non al fine di modificare o influenzare il controllo, e alleghere una procura che autorizza gli ufficiali indicati a presentare le relazioni richieste.
Janus Henderson Group plc inform贸 una participaci贸n minoritaria significativa en American Depositary Shares de Ascendis Pharma A/S. La presentaci贸n muestra una tenencia agregada de 4,427,792 ADS, que representa el 8.0% de la clase, con poder de voto y poder dispositvo compartidos sobre esas acciones. El declarante est谩 constituido en Jersey y se帽ala una oficina principal en el Reino Unido; el emisor tiene su sede en Hellerup, Dinamarca.
Una filial de Janus Henderson, JHIUS, podr铆a considerarse la beneficiaria efectiva de 4,328,772 ADS (7.8%) con los correspondientes poderes de voto y de disposici贸n compartidos. La presentaci贸n incluye una certificaci贸n de que los valores fueron adquiridos en el curso ordinario del negocio y no para cambiar o influir en el control, y adjunta un poder que autoriza a los funcionarios nombrados a presentar los informes requeridos.
Janus Henderson Group plc電� Ascendis Pharma A/S鞚� 氙戈淡鞓堩儊歃濎劀(ADS)鞐� 雽�頃� 靸侂嫻頃� 靻岇垬 歆�攵勳潉 鞁犼碃頄堨姷雼堧嫟. 鞝滌稖 靹滊電� 頃措嫻 韥措灅鞀れ潣 8.0%毳� 彀頃橂姅 齑� 4,427,792 ADS 氤挫湢毳� 氤挫棳欤茧┌, 頃措嫻 欤检嫕鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 鞝�歆�(Jersey)鞐� 靹る霅橃柎 鞓侁淡鞚� 氤胳偓毳� 旮办灛頄堨溂氅�, 氚滍枆須岇偓電� 雿措韥� 項煬耄�(Hellerup)鞐� 氤胳偓毳� 霊愱碃 鞛堨姷雼堧嫟.
Janus Henderson鞚� 鞛愴殞靷� JHIUS電� 4,328,772 ADS(7.8%)鞚� 鞁れ鞝� 靻岇湢鞛�搿� 臧勳＜霅� 靾� 鞛堨溂氅�, 鞚挫棎 靸侅潙頃橂姅 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓岇潉 臧�歆戨媹雼�. 鞝滌稖 靹滊鞐愲姅 頃措嫻 歃濌秾鞚� 鞝曥儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 旆摑霅橃棃鞙茧┌ 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橂牑電� 氇╈爜鞚� 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔霅橃柎 鞛堦碃, 歆�鞝曤悳 鞛勳洂霌れ澊 頃勳殧頃� 氤搓碃靹滊ゼ 鞝滌稖頃� 靾� 鞛堧弰搿� 甓岉暅鞚� 攵�鞐晿電� 鞙勳瀯鞛ル弰 觳秬霅橃柎 鞛堨姷雼堧嫟.
Janus Henderson Group plc a d茅clar茅 une participation minoritaire significative dans les American Depositary Shares d'Ascendis Pharma A/S. Le dossier fait 茅tat d'une d茅tention globale de 4,427,792 ADS, repr茅sentant 8.0% de la cat茅gorie, avec des pouvoirs de vote et de disposition partag茅s sur ces actions. Le d茅clarant est constitu茅 脿 Jersey et indique un bureau principal au Royaume鈥慤ni ; l'茅metteur a son si猫ge 脿 Hellerup, au Danemark.
Une filiale de Janus Henderson, JHIUS, pourrait 锚tre consid茅r茅e comme le propri茅taire effectif de 4,328,772 ADS (7.8%) avec les pouvoirs de vote et de disposition partag茅s correspondants. Le dossier comprend une certification indiquant que les titres ont 茅t茅 acquis dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le, et joint une procuration autorisant les responsables nomm茅s 脿 d茅poser les rapports requis.
Janus Henderson Group plc meldete eine bedeutende Minderheitsbeteiligung an Ascendis Pharma A/S American Depositary Shares. Die Einreichung weist eine gesamte Beteiligung von 4,427,792 ADS aus, die 8.0% der Klasse darstellen, mit gemeinsamem Stimm- und gemeinsamem Verf眉gungsrecht 眉ber diese Aktien. Der Melder ist in Jersey organisiert und nennt ein Hauptb眉ro im Vereinigten K枚nigreich; der Emittent hat seinen Hauptsitz in Hellerup, D盲nemark.
Eine Tochtergesellschaft von Janus Henderson, JHIUS, kann als wirtschaftlicher Eigent眉mer von 4,328,772 ADS (7.8%) angesehen werden und verf眉gt 眉ber die entsprechenden gemeinsamen Stimm- und Verf眉gungsrechte. Die Einreichung enth盲lt eine Best盲tigung, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsverlauf erworben wurden und nicht zum Zweck der 脛nderung oder Beeinflussung der Kontrolle, und f眉gt eine Vollmacht bei, die benannte leitende Angestellte zur Einreichung der erforderlichen Berichte erm盲chtigt.
- Material disclosure of ownership: Aggregate position of 4,427,792 ADSs (8.0%) is clearly reported
- Transparency on voting and dispositive power: Shared voting and shared dispositive power over reported ADSs is disclosed
- Compliance documentation included: Certification of ordinary-course acquisition and a power of attorney for filing authority are attached
- None.
Insights
TL;DR: Janus Henderson holds a material ~8% stake in Ascendis Pharma, disclosed via Schedule 13G, signaling a sizeable passive position.
The filing documents an aggregate position of 4,427,792 ADSs (8.0%) under Janus Henderson Group plc with shared voting and dispositive power. For one subsidiary (JHIUS) the filing reports 4,328,772 ADSs (7.8%). This is a clear disclosure of a large minority stake above the 5% reporting threshold and is consistent with passive investment activity as certified in the filing. From a portfolio viewpoint, the position is material and requires continued monitoring for changes but the filing itself indicates ordinary-course ownership rather than an active control intent.
TL;DR: The Schedule 13G shows regulatory compliance for a >5% holding, with explicit shared voting/dispositive power and a formal POA for filings.
The report identifies Janus Henderson Group plc as the reporting person, organized in Jersey, and discloses shared voting and dispositive authority over 4,427,792 ADSs (8.0%). It also notes a subsidiary-level beneficial ownership of 4,328,772 ADSs (7.8%). The filing includes a certification that the position is held in the ordinary course and a power of attorney dated December 9, 2022, delegating authority to named officers to execute regulatory reports. These elements demonstrate adherence to disclosure obligations without indicating an intent to influence control.
Janus Henderson Group plc ha segnalato una partecipazione minoritaria significativa nelle American Depositary Shares di Ascendis Pharma A/S. La comunicazione indica un detenuto complessivo di 4,427,792 ADS, pari all'8.0% della classe, con poteri di voto e di disposizione condivisi su tali azioni. Il dichiarante 猫 costituito a Jersey e dichiara un ufficio principale nel Regno Unito; l'emittente ha sede centrale a Hellerup, in Danimarca.
Una controllata di Janus Henderson, JHIUS, potrebbe essere considerata il beneficiario effettivo di 4,328,772 ADS (7.8%) con i corrispondenti poteri di voto e di disposizione condivisi. La comunicazione include una certificazione che i titoli sono stati acquisiti nell'ordinaria attivit脿 commerciale e non al fine di modificare o influenzare il controllo, e alleghere una procura che autorizza gli ufficiali indicati a presentare le relazioni richieste.
Janus Henderson Group plc inform贸 una participaci贸n minoritaria significativa en American Depositary Shares de Ascendis Pharma A/S. La presentaci贸n muestra una tenencia agregada de 4,427,792 ADS, que representa el 8.0% de la clase, con poder de voto y poder dispositvo compartidos sobre esas acciones. El declarante est谩 constituido en Jersey y se帽ala una oficina principal en el Reino Unido; el emisor tiene su sede en Hellerup, Dinamarca.
Una filial de Janus Henderson, JHIUS, podr铆a considerarse la beneficiaria efectiva de 4,328,772 ADS (7.8%) con los correspondientes poderes de voto y de disposici贸n compartidos. La presentaci贸n incluye una certificaci贸n de que los valores fueron adquiridos en el curso ordinario del negocio y no para cambiar o influir en el control, y adjunta un poder que autoriza a los funcionarios nombrados a presentar los informes requeridos.
Janus Henderson Group plc電� Ascendis Pharma A/S鞚� 氙戈淡鞓堩儊歃濎劀(ADS)鞐� 雽�頃� 靸侂嫻頃� 靻岇垬 歆�攵勳潉 鞁犼碃頄堨姷雼堧嫟. 鞝滌稖 靹滊電� 頃措嫻 韥措灅鞀れ潣 8.0%毳� 彀頃橂姅 齑� 4,427,792 ADS 氤挫湢毳� 氤挫棳欤茧┌, 頃措嫻 欤检嫕鞐� 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓岇潉 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖鞚胳潃 鞝�歆�(Jersey)鞐� 靹る霅橃柎 鞓侁淡鞚� 氤胳偓毳� 旮办灛頄堨溂氅�, 氚滍枆須岇偓電� 雿措韥� 項煬耄�(Hellerup)鞐� 氤胳偓毳� 霊愱碃 鞛堨姷雼堧嫟.
Janus Henderson鞚� 鞛愴殞靷� JHIUS電� 4,328,772 ADS(7.8%)鞚� 鞁れ鞝� 靻岇湢鞛�搿� 臧勳＜霅� 靾� 鞛堨溂氅�, 鞚挫棎 靸侅潙頃橂姅 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓岇潉 臧�歆戨媹雼�. 鞝滌稖 靹滊鞐愲姅 頃措嫻 歃濌秾鞚� 鞝曥儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 旆摑霅橃棃鞙茧┌ 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橂牑電� 氇╈爜鞚� 鞎勲嫎鞚� 鞚胳頃橂姅 雮挫毄鞚� 韽暔霅橃柎 鞛堦碃, 歆�鞝曤悳 鞛勳洂霌れ澊 頃勳殧頃� 氤搓碃靹滊ゼ 鞝滌稖頃� 靾� 鞛堧弰搿� 甓岉暅鞚� 攵�鞐晿電� 鞙勳瀯鞛ル弰 觳秬霅橃柎 鞛堨姷雼堧嫟.
Janus Henderson Group plc a d茅clar茅 une participation minoritaire significative dans les American Depositary Shares d'Ascendis Pharma A/S. Le dossier fait 茅tat d'une d茅tention globale de 4,427,792 ADS, repr茅sentant 8.0% de la cat茅gorie, avec des pouvoirs de vote et de disposition partag茅s sur ces actions. Le d茅clarant est constitu茅 脿 Jersey et indique un bureau principal au Royaume鈥慤ni ; l'茅metteur a son si猫ge 脿 Hellerup, au Danemark.
Une filiale de Janus Henderson, JHIUS, pourrait 锚tre consid茅r茅e comme le propri茅taire effectif de 4,328,772 ADS (7.8%) avec les pouvoirs de vote et de disposition partag茅s correspondants. Le dossier comprend une certification indiquant que les titres ont 茅t茅 acquis dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le, et joint une procuration autorisant les responsables nomm茅s 脿 d茅poser les rapports requis.
Janus Henderson Group plc meldete eine bedeutende Minderheitsbeteiligung an Ascendis Pharma A/S American Depositary Shares. Die Einreichung weist eine gesamte Beteiligung von 4,427,792 ADS aus, die 8.0% der Klasse darstellen, mit gemeinsamem Stimm- und gemeinsamem Verf眉gungsrecht 眉ber diese Aktien. Der Melder ist in Jersey organisiert und nennt ein Hauptb眉ro im Vereinigten K枚nigreich; der Emittent hat seinen Hauptsitz in Hellerup, D盲nemark.
Eine Tochtergesellschaft von Janus Henderson, JHIUS, kann als wirtschaftlicher Eigent眉mer von 4,328,772 ADS (7.8%) angesehen werden und verf眉gt 眉ber die entsprechenden gemeinsamen Stimm- und Verf眉gungsrechte. Die Einreichung enth盲lt eine Best盲tigung, dass die Wertpapiere im gew枚hnlichen Gesch盲ftsverlauf erworben wurden und nicht zum Zweck der 脛nderung oder Beeinflussung der Kontrolle, und f眉gt eine Vollmacht bei, die benannte leitende Angestellte zur Einreichung der erforderlichen Berichte erm盲chtigt.
FAQ
What stake does Janus Henderson report in Ascendis Pharma (ASND)?
Does any Janus Henderson subsidiary own Ascendis ADSs separately?
What class of Ascendis securities is being reported?
Does the filing indicate an intent to influence control of Ascendis Pharma?
Who signed the Schedule 13G on behalf of Janus Henderson?
Is there authorization for individuals to file reports for Janus Henderson?
